Sakar Healthcare (NSE:SAKAR) Beta: 0.3170 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAKAR Sakar Healthcare Ltd NSE:SAKAR
60 GF Score
Price ₹904.45
GF Value ₹540.00
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sakar Healthcare Beta?

Sakar Healthcare NSE:SAKAR +4.74% 60 Beta is 0.3170 as of Jul. 15, 2026. GuruFocus rates NSE:SAKAR with a GF Score™ of 60/100 and a GF Value™ of ₹540.00 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-15), Sakar Healthcare's Beta is 0.3170.


Sakar Healthcare  (NSE:SAKAR) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Sakar Healthcare Beta Related Terms


Sakar Healthcare Beta Historical Data

* Premium members only.

The historical data trend for Sakar Healthcare's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sakar Healthcare Beta Chart

Sakar Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 0.92 1.23 0.78 0.28

Sakar Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 1.16 0.95 0.45 0.28

NSE:SAKAR vs ZTS, UTHR: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sakar Healthcare's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sakar Healthcare Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sakar Healthcare's Beta distribution charts can be found below:

* The bar in red indicates where Sakar Healthcare's Beta falls into.


NSE:SAKAR
60GF Score
Sakar Healthcare Ltd NSE:SAKAR
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sakar Healthcare Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.3170 mean?
Sakar Healthcare (NSE:SAKAR) has a Beta of 0.3170 as of Jul. 15, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Sakar Healthcare and its competitors.
Is Sakar Healthcare's Beta too high?
Sakar Healthcare's current Beta is 0.3170. Overall, Sakar Healthcare has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakar Healthcare's Beta compare to ZTS and UTHR?
Sakar Healthcare's Beta of 0.3170 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Sakar Healthcare and its competitors. Sakar Healthcare's current Beta is 0.3170. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakar Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sakar Healthcare (NSE:SAKAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹540.00, compared to a current price of ₹904.45 — trading 67.5% above its estimated fair value. The current Beta is 0.3170. Sakar Healthcare's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Sakar Healthcare (NSE:SAKAR), the current Beta is 0.3170 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sakar Healthcare (NSE:SAKAR) Overvalued in 2026?

Based on GuruFocus' analysis, Sakar Healthcare stock appears to be overvalued. The current stock price of ₹904.45 is trading 67.5% above its estimated GF Value™ of ₹540.00. GuruFocus considers Sakar Healthcare to be Significantly Overvalued.

Key valuation signals for NSE:SAKAR:

  • Beta: 0.3170
  • GF Value™: ₹540.00 vs. price of ₹904.45 (67.5% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the NSE:SAKAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sakar Healthcare Business Description

Address 406, Silver Oaks Comm. Complex, Opposite Arun Society, Paldi, Ahmedabad, GJ, IND, 382 007
Sakar Healthcare Ltd is engaged in manufacturing Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. The company offers its products to Sri Lanka, the Philippines, Vietnam, Cambodia, Sudan, Myanmar, Mauritius, Costa Rica, Panama, El Salvador and Paraguay.
60GF Score

Get the complete analysis for NSE:SAKAR

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹904.45
Price
₹540.00
GF Value